MLEC icon

Moolec Science
MLEC

1 day
0.00%
5 days
0.00%
1 month
0.00%
3 months
0.00%
6 months
0.00%
Year to date
0.00%
1 year
0.00%
5 years
0.00%
10 years
0.00%
 

About: Moolec Science SA is a science-based ingredient company focused on producing real animal proteins in plants through Molecular Farming, a technology in the alternative protein landscape. Its purpose is to upgrade the taste, nutrition, and affordability of alternative protein products while building a more sustainable and equitable food system. The company has various products in its pipeline such as; TSP Valorasoy which is a soy protein product to produce vegetable proteins with texture and fibrousness similar to those of meat, Glaso, a safflower oil with high levels of gamma-linolenic acid, SPC2 which is a plant-based chymosin, YEEA1, an extract derived from a novel yeast biomass with specific properties, and others. The company's revenues arise from operations in Argentina.

Employees: 52

0
Funds holding %
of 7,296 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

50% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 2

46% more capital invested

Capital invested by funds: $56.2K [Q4 2024] → $82K (+$25.8K) [Q1 2025]

13% more funds holding

Funds holding: 8 [Q4 2024] → 9 (+1) [Q1 2025]

0.2% more ownership

Funds ownership: 0.18% [Q4 2024] → 0.38% (+0.2%) [Q1 2025]

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

Research analyst outlook

We haven’t received any recent analyst ratings for MLEC.

Financial journalist opinion

Neutral
Accesswire
4 days ago
Moolec Science Regains NASDAQ Compliance
GRAND CAYMAN, CAYMAN ISLANDS / ACCESS Newswire / June 11, 2025 / Moolec Science SA (NASDAQ:MLEC) "The Company"; "Moolec"), a science-based food ingredient company focused on producing animal proteins and nutritional oils in plants, today announced that it regained compliance with Listing Rule 5550(a)(2) (the "Bid Price Rule"), as required by the Nasdaq Hearings Panel's ("Panel") decision dated April 3, 2025. On May 14, 2025, the Company effected a 1-for-10 reverse stock split, and the common shares have since had a closing bid price of at least $1.
Moolec Science Regains NASDAQ Compliance
Neutral
Accesswire
1 month ago
Moolec Science Announces Effectiveness of Reverse Stock Split
LUXEMBOURG, LU / ACCESS Newswire / May 12, 2025 / Moolec Science SA (NASDAQ:MLEC; the "Company" or "Moolec"), a science-based food ingredient company focused on producing animal proteins and nutritional oils in plants, today announced that, in accordance with the resolutions passed at the extraordinary general meeting of shareholders held on April 22, 2025, and the resolutions adopted by the Company's board of directors on the same date, the Company has approved a reverse stock split at a consolidation ratio of one-for-ten (1-for-10). As a result, every ten ordinary shares of the Company, with a par value of US$0.01 per share (the "Shares"), issued and outstanding will automatically, and without any action required on the part of the holders, be consolidated into one validly issued, fully paid, and non-assessable Share, with no change to the par value per share (the "Reverse Stock Split").
Moolec Science Announces Effectiveness of Reverse Stock Split
Neutral
Accesswire
1 month ago
Moolec Science Enters Into Transformational Transaction Expanding Across Multiple Technology Platforms
LUXEMBOURG, LU / ACCESS Newswire / April 21, 2025 / Moolec Science SA (NASDAQ:MLEC) ("The Company" or "Moolec"), a science-based food ingredient company focused on producing animal proteins and nutritional oils in plants, today announced that it has entered into a Business Combination Agreement (the "BCA") with Bioceres Group Limited ("Bioceres Group") and other related entities in an all-stock transaction (the "Business Combination"). Subject to the terms and conditions of the BCA, which was signed on April 17, 2025, several parties will transfer their respective holdings in Bioceres Group, Nutrecon LLC ("Nutrecon"), and Gentle Technologies Corp ("Gentle Tech", and together with Bioceres Group and Nutrecon, the "Contributed Entities"), resulting in an enlarged corporate structure with Moolec as the parent company.
Moolec Science Enters Into Transformational Transaction Expanding Across Multiple Technology Platforms
Neutral
Accesswire
1 month ago
Moolec Science Enters Into Transformational Transaction Expanding Across Multiple Technology Platforms
LUXEMBOURG, LU / ACCESS Newswire / April 21, 2025 / Moolec Science SA (NASDAQ:MLEC) ("The Company" or "Moolec"), a science-based food ingredient company focused on producing animal proteins and nutritional oils in plants, today announced that it has entered into a Business Combination Agreement (the "BCA") with Bioceres Group Limited ("Bioceres Group") and other related entities in an all-stock transaction (the "Business Combination"). Subject to the terms and conditions of the BCA, which was signed on April 17, 2025, several parties will transfer their respective holdings in Bioceres Group, Nutrecon LLC ("Nutrecon"), and Gentle Technologies Corp ("Gentle Tech", and together with Bioceres Group and Nutrecon, the "Contributed Entities"), resulting in an enlarged corporate structure with Moolec as the parent company.
Moolec Science Enters Into Transformational Transaction Expanding Across Multiple Technology Platforms
Neutral
Accesswire
2 months ago
Moolec Received Nasdaq Staff Determination Letter
LUXEMBOURG, LU / ACCESS Newswire / March 17, 2025 / Moolec Science SA (NASDAQ:MLEC), a public limited liability company (société anonyme) governed by the laws of the Grand Duchy of Luxembourg, having its registered office at 17, Boulevard F.W. Raiffeisen, L-2411 Luxembourg, Grand Duchy of Luxembourg, and registered with the Luxembourg Register of Commerce and Companies (Registre de Commerce et des Sociétés de Luxembourg) under registration number B268440 ("Moolec," the "Company," "we," "us" or "our") received a letter on March 11, 2025 (the "Determination Letter"), from the staff of the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that, as the closing bid price of its listed securities has remained at less than $1.00 per share over 30 consecutive business days as of September 10, 2024, and has not increased to $1.00 for more than 10 consecutive business days thereafter, the Company has not regained compliance with Nasdaq Listing Rule 5550(a)(2).
Moolec Received Nasdaq Staff Determination Letter
Neutral
Accesswire
7 months ago
Moolec Has Received USDA Approval for the First Genetically Modified Pea in History
LUXEMBOURG / ACCESSWIRE / October 16, 2024 / Moolec Science SA (NASDAQ:MLEC) ("the Company"), a leader in Molecular Farming technology, announced today that the U.S. Department of Agriculture's ("USDA") Animal and Plant Health Inspection Service ("APHIS") has completed its Regulatory Status Review ("RSR") for the Company's genetically engineered ("GE") peas which produce iron through bovine meat proteins. This is the third regulatory clearance from USDA-APHIS achieved by Moolec in an 18-month window, alongside its genetically engineered safflower and soybean for GLASO™ and Piggy Sooy™ products, respectively.
Moolec Has Received USDA Approval for the First Genetically Modified Pea in History
Neutral
Seeking Alpha
8 months ago
Moolec Science (MLEC) Q4 2024 Earnings Call Transcript
Moolec Science SA (NASDAQ:MLEC ) Q4 2024 Earnings Conference Call October 2, 2024 8:30 AM ET Company Participants Gaston Paladini - Chief Executive Officer Jose Lopez Lecube - Chief Financial Officer Martin Salinas - Chief Technology Officer Amit Dhingra - Chief Science Officer Bill Zima - ICR Strategic Communications Conference Call Participants Scott Fortune - Roth Capital Operator Good morning and welcome to Moolec Science's fourth quarter and full fiscal year 2024 conference call. My name is Bill Zima of ICR Strategic Communications and Advisory.
Moolec Science (MLEC) Q4 2024 Earnings Call Transcript
Neutral
Accesswire
8 months ago
Moolec Science Presents Fiscal Year 2024 Annual Business Update
LUXEMBOURG / ACCESSWIRE / October 2, 2024 / Moolec Science SA (NASDAQ:MLEC) ("The Company"; "Moolec"), a science-based food ingredient company focused on producing animal proteins and nutritional oils in plants, today reported its Business Update for the fourth quarter of Fiscal Year 2024 ended June 30, 2024. Moolec Science Logo The main highlights of Moolec's fourth quarter are as follows: GLASO™: The Company announced an offtake agreement with a major global CPG food and pet food company and an R&D collaboration agreement with Bunge.
Moolec Science Presents Fiscal Year 2024 Annual Business Update
Neutral
Accesswire
8 months ago
Moolec Science to Host Fourth Quarter Fiscal Year 2024 Business Update Conference Call
LUXEMBOURG / ACCESSWIRE / September 25, 2024 / Moolec Science SA (NASDAQ:MLEC)("The Company"; "Moolec"), a science-based food ingredient company focused on producing animal proteins and nutritional oils in plants, announced today that it will release its Business Update for the Fourth Quarter and Full Fiscal Year 2024 on Wednesday, October 2, 2024, before the market opens. Moolec Sciences Logo Moolec's Chief Executive Officer Gastón Paladini, Chief Financial Officer José López Lecube, and Chief Science Officer Amit Dhingra, will host a live Conference Call, followed by a question-and-answer session, on Wednesday, October 2, 2024 at 08:30am ET.
Moolec Science to Host Fourth Quarter Fiscal Year 2024 Business Update Conference Call
Neutral
Accesswire
9 months ago
Moolec Received NASDAQ Bid Price Letter
LUXEMBOURG / ACCESSWIRE / September 13, 2024 / Moolec Science SA (NASDAQ:MLEC) ("The Company", "Moolec"), a science-based food ingredient company, announced today that it received a letter (the "Nasdaq Bid Price Letter") from Nasdaq notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company's ordinary shares has been below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2). The Nasdaq Bid Price Letter has no immediate effect on the listing of the Company's common stock, and its common stock will continue to trade on The Nasdaq Capital Market under the symbol "MLEC".
Moolec Received NASDAQ Bid Price Letter
Charts implemented using Lightweight Charts™